Lupin
LUPIN
Lupin Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | 3.62% | 5,12,680 |
| Weekly | 2.34% | 26,87,146 |
| Monthly | 14.98% | 2,40,57,406 |
Lupin Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| LUPIN | 3.62% | 2.34% | 14.98% |
| Index | - | - | - |
| Peer Avg. | 1.75% | 5.42% | 11.19% |
Lupin Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| LUPIN | 37.44 | 2.36 | 26.89 | -6.42 | -3.79 | 0.53 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Lupin Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 7.33% | -169.04% | -6.42% | -3.79% |
| FY '20-21 | -4.83% | 310.56% | 8.26% | 9.45% |
| FY '19-20 | -1.20% | -98.73% | 1.07% | 6.20% |
Lupin Shareholding Pattern
Lupin Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 14,088.58 | 13,878.47 | 427.52 | -849.21 |
| FY '20-21 | 13,109.44 | 10,803.98 | 2,438.16 | 1,242.61 |
| FY '19-20 | 13,931.11 | 11,740.13 | 2,670.45 | 226.91 |
Lupin Share Price
Lupin Limited is an Indian pharmaceutical company. The company manufactures, develops and markets a variety of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) worldwide. The company operates in the Cardiovascular, Diabetes, Asthma, Pediatric, CNS, Gastrointestinal, Anti-Infective and Non-Steroidal Anti-Inflammatory drug therapeutic segments and operates in the Anti-Tuberculosis and Cephalosporin segments. The company and its subsidiaries have manufacturing facilities in India, the United States, Mexico and Brazil, and trading and other ancillary and related activities also extend to global markets. Its complex generic portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol, among others. Its biosimilars include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim), and Etanercept.